Back to News
Market Impact: 0.28

CIBC cuts Gildan Activewear stock price target on moderated EPS By Investing.com

GILHBI
Analyst EstimatesAnalyst InsightsCorporate EarningsCorporate Guidance & OutlookCompany FundamentalsM&A & Restructuring
CIBC cuts Gildan Activewear stock price target on moderated EPS By Investing.com

CIBC cut its price target on Gildan Activewear to $77 from $79 while keeping an Outperform rating, citing slightly moderated EPS forecasts, but still sees upside into 2027 as the Hanes integration progresses. Gildan reported Q1 2026 adjusted EPS of $0.43, beating the $0.3943 consensus, and revenue of $1.17 billion versus $1.15 billion expected. The company reiterated guidance, including 20% to 25% EPS growth for 2026, though inventory headwinds are expected to persist into Q2.

Analysis

The key takeaway is not the modest target revision itself, but that the market is beginning to separate earnings quality from reported growth for GIL: the near-term multiple is being supported by integration-driven accretion, while the operational reset at Hanes creates a longer-duration rerating path. That is a classic “good quarter, better setup” situation, but the stock’s elevated P/E means the market is already paying for a clean execution path, so any slippage in inventory normalization or integration cadence can compress the multiple quickly. Second-order, the share gain story is more important than the headline EPS beat. If GIL is taking share in both channels while the category remains mixed, weaker incumbents and private-label competitors likely face margin pressure before volumes visibly roll over; that tends to show up first in promotional intensity and channel inventory, not in reported unit declines. The real risk is that GIL’s growth is partly pull-forward from restructuring and distribution gains, which can fade if retailers re-balance assortments or if the company has to fund the Hanes turnaround with more working capital than investors expect. The setup is bullish over 6-18 months but fragile over the next 1-2 quarters. Near term, the stock is vulnerable if investors extrapolate 2027 upside too aggressively before the inventory overhang clears; medium term, the catalyst is continued guidance credibility and evidence that the Hanes integration is producing not just earnings lift but sustained gross margin and free cash flow conversion. Consensus appears to be underestimating how much of the rerating depends on proof, not promise: if execution stays tight, upside can persist; if not, the high multiple leaves little cushion.